- Home
- HWH vs GTBP Comparison
HWH vs GTBP Comparison
Compare HWH & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HWH | GTBP |
|---|---|---|
| Founded | 2021 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 8.8M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HWH | GTBP |
|---|---|---|
| Price | $1.68 | $0.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 743.1K | ★ 1.6M |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.37 | 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $866,926.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $0.26 |
| 52 Week High | $7.77 | $3.73 |
Technical Indicators
Market Signals| Indicator | HWH | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 75.77 | 58.22 |
| Support Level | $1.00 | $0.40 |
| Resistance Level | $1.85 | $0.59 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 42.50 | 85.84 |
Price Performance
Historical ComparisonAbout HWH HWH International Inc.
HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.